About 100 reports

  • BLOOD DISEASE DRUGS
  • Blood Disease Drugs Industry Structure

Cobamamide is one important Blood Disease Drugs in China.

  • Blood Disease
  • China
  • Eisai Co., Ltd.
  • Roche Pharmaceutical Co., Ltd
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • BLOOD DISEASE DRUGS
  • Demand of Blood Disease Drugs by Region

Cobamamide is one important Blood Disease Drugs in China.

  • Blood Disease
  • China
  • Demand
  • Eisai Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • Blood Disease Drugs Imports
  • Other Blood Disease Drugs

In 2008, Inosine import contribution to Blood Disease Drugs was ##. ##% while the figure was ##% in 2013 and ##. ##% in 2018.

  • Blood Disease
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd
  • MAY 06, 2016: DRUG-LIKE COMPOUND SHOWS PROMISE IN TREATING TWO BLOOD DISEASES
  • DEC 11, 2017: ITALFARMACO PRESENTS POSITIVE PHASE II STUDY RESULTS FOR GIVINOSTAT IN POLYCYTHEMIA VERA PATIENTS AT THE ASH ANNUAL MEETING

MAY ##, 2016: DRUG-LIKE COMPOUND SHOWS PROMISE IN TREATING TWO BLOOD DISEASES Rivella and colleagues published their study online today in the journal Blood.

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative

AFTER DONATION, EACH UNIT OF DONATED BLOOD IS REQUIRED TO UNDERGO A SERIES OF TESTS FOR INFECTIOUS DISEASES, INCLUDING: ##.

  • Blood Disease
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited

ONE STUDY, " REDUCING BLOOD SAMPLING FOR CIRCULATING BLOOD VOLUME DETERMINATION: A PILOT FEASIBILITY, " SHOWED A ##% AGREEMENT IN CRITICALLY-ILL COHORTS WHOSE BLOOD VOLUMES WERE COMPARED USING ONE BLOOD DRAW VERSUS FIVE BLOOD DRA

  • Blood Disease
  • Clinical Trial
  • Company
  • Company Financials
  • Demand
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • The content of this press release is solely the views of its authors and does not represent the official views of the National Institutes of Health.

May ##, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases Rivella and colleagues published their study online today in the journal Blood.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Additional Areas in Sickle Cell Disease Date and Time: Thursday, October ##, 2017, ##:##-##:## p. m.

  • Blood Disease
  • Therapy
  • World
  • Company Operations
  • Roche Group
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012

Polycythemia Vera is a rare blood disease characterized by an increased number of red blood cells, white blood cells and platelets, which significantly raises the risk for thromboembolic and hemorrhagic complications.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • NOV 02, 2018: NOVARTIS TO PRESENT NEW DATA ON CRIZANLIZUMAB AT 2018 ASH ANNUAL MEETING
  • (SPARTAN). The trial was registered with the U.S. National Institutes of Health.

Blood tests revealed her pain stemmed from a form of sickle cell disease.

  • Blood Disease
  • Hospital
  • Therapy
  • United States
  • Product Initiative
  • HEMOPURIFIER - PRODUCT DESCRIPTION

THE COMPANY DEVELOPS BIOMIMETIC BLOOD PERFUSION DEVICES FOR DISEASE PREVENTION OR MANAGEMENT.

  • Blood Disease
  • Clinical Trial
  • United States
  • Company
  • CytoSorbents Corporation
  • Jun 06, 2019: FDA agrees to review Celgene-Acceleron's luspatercept in anaemia
  • Apr 26, 2019: Celgene and Acceleron Pharma announce submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia

One pediatric patient is still receiving regular blood transfusions.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
  • M-009 - Drug Profile

In beta-thalassemia, a long-studied genetic disorder, a mutation impairs hemoglobin production, resulting in defective red blood cells (RBCs).

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • BIOMARKER ASSAY - SEPSIS - PRODUCT DESCRIPTION

Liquid biopsy: Detection of cancer or other diseases by testing bodily fluids such as blood.

  • Blood Disease
  • Clinical Trial
  • CT Scan
  • Medical Device
  • Grifols, S.A.
  • 7.1 OVERVIEW

', Blood advances.

  • Blood Disease
  • Novo Nordisk Group
  • Pfizer Inc.
  • Roche Group
  • Takeda Pharmaceutical Company Limited
  • SPINIT DEVICE - THROMBOCYTOPENIA ASSAY - PRODUCT DESCRIPTION
  • DIAGNOSTIC TEST - HEMOPHILIA - PRODUCT DESCRIPTION

From ## of these players, blood samples were taken ##, ##, ## and ## hours (six days) after the concussion.

  • Blood Disease
  • Drug Development
  • In Vitro Diagnostic Reagent
  • Point Of Care Testing
  • Siemens Healthcare GmbH
  • Clinical Trials

Enrollment and treatment are ongoing in Part ## of the Phase ## trial in patients with CMT disease.

  • Blood Disease
  • Pharmaceutical
  • United States
  • World
  • Acceleron Pharma, Inc.
  • Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) - Product Development Milestones
  • LUSPATERCEPT - DRUG PROFILE

ACE-## is being evaluated in two Phase II trials, one in facioscapulohumeral muscular dystrophy (FSHD) and one in CMT disease.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Acceleron Pharma, Inc.
  • Hematology Drugs Market Historic Growth

Hematology drugs market offers drugs, blood and blood products that are used for the treatment of diseases such as rare genetic disorders, anemia, and conditions related to sickle cell disease and other related diseases.

  • Blood Disease
  • World
  • Bayer AG
  • Novo Nordisk Group
  • Shire plc
  • AUG 01, 2019: HEALTH MINISTRY TO REIMBURSE NOVARTIS' REVOLADE TREATING SEVERE APLASTIC ANEMIA
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

People with the disease have abnormally low levels of platelets in the blood.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • BioLineRx Ltd.
  • Fanconi Anemia - Drug Profiles
  • Fanconi Anemia - Companies Involved in Therapeutics Development

" In the Spanish Phase ## trial, RP-L## has shown strong safety and promising efficacy to date, with durable engraftment in peripheral blood and bone marrow.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Boehringer Ingelheim GmbH

PV and ET, along with myelofibrosis (MF), are blood cancers that belong to a group of diseases known as myeloproliferative neoplasms (MPNs).

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation

Polycythemia Vera is a rare blood disease characterized by an increased number of red blood cells, white blood cells and platelets, which significantly raises the risk for thromboembolic and hemorrhagic complications.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • Dec 04, 2017: La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC-401 in Patients With Beta Thalassemia
  • M-009 - DRUG PROFILE

VCN in peripheral blood was ##. ##copies/ genome at ## month after LentiGlobin infusion.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • EON 100 AUTOMATED CHEMISTRY ANALYZER - UIBC ASSAY PRODUCT OVERVIEW
  • EON 300 AUTOMATED CHEMISTRY ANALYZER - UIBC ASSAY - PRODUCT DESCRIPTION

Transferrin Tests A ferritin blood test measures the amount of ferritin in the blood.

  • Blood Disease
  • Clinical Trial
  • In Vitro Diagnostic Reagent
  • In Vitro Diagnostics
  • ELITECHGROUP INC.
  • 5. All the trials included are unique trials.

Hoffmann-La Roche Ltd ## Jul 2018 ## Jul 2033 ## ## New York Blood Center National Cord Blood Program New York Blood Center National Cord Blood Program GDCT## NCT##, ## Hematological Disorders Anemia, Aplastic Anemia, Leukemia, Lymphoma

  • Blood Disease
  • Clinical Trial
  • Drug Development
  • Leukemia
  • Novartis AG
  • JUL 09, 2018: CELGENE AND ACCELERON ANNOUNCE LUSPATERCEPT ACHIEVED PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PHASE III 'BELIEVE' STUDY IN ADULTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA

ACE-## is currently being evaluated in two Phase ## trials: one in FSHD and one in Charcot-Marie-Tooth (CMT) disease.

  • Blood Disease
  • Therapy
  • United States
  • Product Initiative
  • Acceleron Pharma, Inc.
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Product Development Milestones

Protagonist is developing PTG-## for the treatment of anemia and iron overload in related rare blood disorder diseases, including beta thalassemia.

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Product Development Milestones

Protagonist is developing PTG-## for the treatment of anemia and iron overload in related rare blood disorder diseases, including beta thalassemia.

  • Blood Disease
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • Fanconi Anemia - Drug Profiles
  • Fanconi Anemia - Companies Involved in Therapeutics Development

The organization is developing medicines for rare neuromuscular diseases, liver diseases, blood and eye disorders.

  • Blood Disease
  • Therapy
  • United States
  • World
  • Product Initiative